Young child with Doctor


Latest press releases

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
30 September 2015
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)
24 September 2015
AstraZeneca to present data demonstrating diversity of its portfolio of innovative formulations and devices at the European Respiratory Society International Congress 2015
22 September 2015
AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes
17 September 2015
AstraZeneca announces new tolerability, long-term efficacy and real-world adherence data for exenatide once weekly in patients with type 2 diabetes
15 September 2015
AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015
11 September 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
11 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
8 September 2015
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015
4 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
3 September 2015
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
2 September 2015

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

H1 2015 results

30 July 2015

The following slides are available to download for the media.

Download presentation (PDF 1029kb)

Photo and video library

AstraZeneca in Cambridge

Broadcast video

Board and management



Operations and Manufacturing

Research & Development

Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.